Mga Batayang Estadistika
| CIK | 1377121 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Protagonist Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGO |
|
| August 6, 2025 |
Exhibit 99.1 Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastr |
|
| August 6, 2025 |
Calculation of Filing Fee Tables S-3 Protagonist Therapeutics, Inc Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, $0. |
|
| August 6, 2025 |
Form of indenture of subordinated debt securities and related form of subordinated debt security. Exhibit 4.3 PROTAGONIST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities INDENTURE INDENTURE, dated as of [●], 202[●], among PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE] as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and del |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission August 6, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission August 6, 2025 Registration No. |
|
| August 6, 2025 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 PROTAGONIST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities INDENTURE INDENTURE, dated as of [●], 202[●], among PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE] as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| June 26, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| May 6, 2025 |
Exhibit 99.1 Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAG |
|
| May 6, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2025 |
Exhibit 99.1 Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotr |
|
| March 11, 2025 |
Exhibit 99.2 Protagonist Reports Positive Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative Colitis Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28 All three doses met the primary endpoint of clinical respons |
|
| March 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 (March 8, 2025) PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of in |
|
| March 10, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| March 10, 2025 |
Exhibit 99.1 Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotr |
|
| March 10, 2025 |
Exhibit 99.2 Protagonist Reports Positive Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative Colitis Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28 All three doses met the primary endpoint of clinical respons |
|
| March 3, 2025 |
Exhibit 99.1 News Release Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfe |
|
| March 3, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| March 3, 2025 |
Exhibit 99.2 Phase 3 VERIFY Study Topline Results March 3, 2025 Dinesh V. Patel, Ph.D. Director, President, and CEO Arturo Molina, M.D., M.S. Chief Medical Officer Protagonist Therapeutics, Inc. Newark, CA 1 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securit |
|
| February 21, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (“we,” “us,” “our,” or the “Company”). The following summaries and descriptions are not complete and are subject to and qualified by reference to the a |
|
| February 21, 2025 |
Exhibit 99.1 Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update $165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in |
|
| February 21, 2025 |
Exhibit 19.1 INSIDER TRADING AND TRADING WINDOW POLICY Frequently Asked Questions 1. What is insider trading? A: Insider trading is the buying or selling of stocks, bonds, futures, or other securities by someone in possession of material, non-public information. Insider trading also includes trading in derivative securities (puts and calls), the price of which is linked to the underlying price of |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025. As filed with the Securities and Exchange Commission on February 21, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or o |
|
| February 21, 2025 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia |
|
| February 21, 2025 |
Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 Protagonist Therapeutics, Inc Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0. |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| February 21, 2025 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| February 10, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Com |
|
| November 18, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| November 18, 2024 |
Exhibit 99.1 Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113) in plaque psoriasis, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC- |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga207422ptgx11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PR |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| November 7, 2024 |
Exhibit 99.1 Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for |
|
| October 16, 2024 |
PTGX / Protagonist Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G 1 ProtagonistTheraInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PROTAGONIST THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 74366E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) ( |
|
| August 6, 2024 |
Exhibit 99.1 Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase 2b ANTHEM clinical trial in moderate-to-severe ulcerative colitis expected to complete the primary |
|
| August 6, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGO |
|
| August 6, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 6th day of May, 2024, by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership (“Landlord”), and PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of March 6, 2017 ( |
|
| June 26, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROTAGONIST THERAPEUTICS, INC. Protagonist Therapeutics, Inc. (the “Company” or the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is Prota |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2024 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT by and between Protagonist Therapeutics, Inc. and Takeda Pharmaceuticals USA, Inc. Dated as of January 31, 2024 [***] = CERTAIN CONFI |
|
| May 7, 2024 |
Exhibit 99.1 Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 20271 Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis is now complete Data from the Phase 2b FRONTIER 2, a |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAG |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024. As filed with the Securities and Exchange Commission on February 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or organi |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST |
|
| February 27, 2024 |
Exhibit 97.1 PROTAGONIST THERAPEUTICS, INC. COMPENSATION RECOUPMENT (CLAWBACK) POLICY (as adopted November 28, 2023) Recoupment of Incentive-Based Compensation It is the policy of Protagonist Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial repor |
|
| February 27, 2024 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| February 27, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (“we,” “us,” “our,” or the “Company”). The following summaries and descriptions are not complete and are subject to and qualified by reference to the a |
|
| February 27, 2024 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Protagonist Therapeutics, Inc. |
|
| February 27, 2024 |
Exhibit 99.1 Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 20271 Two articles published in the New England Journal of Medicine |
|
| February 14, 2024 |
PTGX / Protagonist Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Protagonist Therapeutics, Inc (Name of Issuer) Common Stock, par value $0.00001 per share (the “Shares”) (Title of Class of Securities) 743 |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the ru |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 13, 2024 |
PTGX / Protagonist Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01749-protagonisttherapeut.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Protagonist Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 74366E102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 7, 2024 |
SC 13G/A 1 p24-0421sc13ga.htm PROTAGONIST THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of |
|
| February 2, 2024 |
PTGX / Protagonist Therapeutics, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Com |
|
| January 16, 2024 |
Exhibit 99.1 1 JP Morgan 42 nd Annual Healthcare Conference Dinesh V. Patel, Ph.D. President & CEO January 09, 2024 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts |
|
| January 8, 2024 |
COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO January 08, 2024 1 Exhibit 99.1 COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO January 08, 2024 1 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presenta t |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Com |
|
| December 18, 2023 |
SC 13G 1 p23-2990sc13g.htm PROTAGONIST THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 7, 2023 (Date of Event Which Requires Filing of this St |
|
| December 18, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p23-2990exhibit991.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional |
|
| November 2, 2023 |
Exhibit 99.1 Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023) Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral IL-23 receptor antagonist peptide drug candidate f |
|
| November 2, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PR |
|
| November 2, 2023 |
Exhibit 10.1 PROTAGONIST THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ] Protagonist Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its permitted registered ass |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| August 11, 2023 |
2,750,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-227216 Prospectus Supplement (To the Prospectus dated September 21, 2018) 2,750,000 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated September 21, 2018 (the “Original Prospectus”), relating to the disposition, from time to time, of up to 2,750,000 shares (the |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGO |
|
| August 3, 2023 |
Exhibit 99.1 Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe plaque psoriasis, presented at the World Congress of Dermatology. JNJ-2113 now advances toward |
|
| August 3, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| July 5, 2023 |
1 COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO July 04, 2023 Exhibit 99.1 1 COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO July 04, 2023 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this pre sentation |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 4, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2023 |
Exhibit 99.1 Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide for the treatment of moderate-to-severe plaque psoriasis; additional data to be shared at medical conferences beginning in Q2 2023 Announced positive topline results fro |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAG |
|
| April 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) April 3, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 10, 2023 |
Underwriting Agreement, dated April 4, 2023 Exhibit 1.1 5,000,000 Shares Protagonist Therapeutics, Inc. UNDERWRITING AGREEMENT April 4, 2023 J.P. MORGAN SECURITIES LLC JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Sandler & Co. 800 Nicollet Mall, |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| April 6, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-266595 PROSPECTUS SUPPLEMENT (To prospectus dated August 16, 2022) 5,000,000 Shares Common stock We are offering 5,000,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Market, or Nasdaq, under the symbol “PTGX.” On |
|
| April 4, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated April 4, 2023 TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. |
|
| March 20, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 20, 2023 with respect to the shares of Common Stock, par value $0.00001 per share, of Protagonist Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and |
|
| March 20, 2023 |
PTGX / Protagonist Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP |
|
| March 15, 2023 |
Exhibit 10.25 Protagonist Therapeutics Inc 7707 Gateway Blvd., Ste 140 Newark, CA 94560 United States of America Tel + 1 510 474-0170 www.protagonist-inc.com November 1, 2022 Arturo Molina [mailing address] [telephone number] [email address] Dear Arturo, On behalf of Protagonist, a biopharmaceutical company dedicated to discovering and developing peptides as novel pharmaceutical drugs, I am happy |
|
| March 15, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (“we,” “us,” “our,” or the “Company”). The following summaries and descriptions are not complete and are subject to and qualified by reference to the a |
|
| March 15, 2023 |
Exhibit 99.1 Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE |
|
| March 15, 2023 |
Exhibit 10.26 EMPLOYEE SEVERANCE AGREEMENT THIS EMPLOYEE SEVERANCE AGREEMENT (this “Agreement”) is entered into as of the 7th day of November, 2022, by and between Protagonist Therapeutics, Inc., a Delaware corporation (the”Company”), and Arturo Molina, M.D. (the”Employee”). Statement of Purpose WHEREAS, Employee is currently employed by the Company as an at-will employee; WHEREAS, notwithstanding |
|
| March 15, 2023 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia |
|
| March 15, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES 4 tm238766d1ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Protagonist Therapeutics, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par v |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST |
|
| March 15, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023. As filed with the Securities and Exchange Commission on March 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or organizat |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2023 |
EX-99.1 2 pt7213gab.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| February 14, 2023 |
SC 13G/A 1 p23-0494sc13ga.htm PROTAGONIST THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2022 (Date of event which requires filing of |
|
| February 14, 2023 |
SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Protagonist Therapeutics, Inc. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP |
|
| February 9, 2023 |
PTGX / Protagonist Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 13ga5protagonist.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) * Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Ch |
|
| February 9, 2023 |
PTGX / Protagonist Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Protagonist Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 74366E102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| January 11, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, $.00001 par value (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2022 |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2023 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Com |
|
| January 3, 2023 |
EX-99.1 2 tm231435d1ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Protagonist Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Excha |
|
| January 3, 2023 |
PTGX / Protagonist Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment SC 13G 1 tm231435d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (the “Shares” |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2022 |
Exhibit 99.1 Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina, M.D., M.S. named Chief Medical Officer, providing medical, clinical development, and strategic leadership to the rusfertide clinical development program Three rusfertide poster presentations to be shared at |
|
| August 12, 2022 |
PROTAGONIST THERAPEUTICS, INC. 7707 Gateway Boulevard, Suite 140 Newark, CA 94560 CORRESP 1 filename1.htm PROTAGONIST THERAPEUTICS, INC. 7707 Gateway Boulevard, Suite 140 Newark, CA 94560 VIA EDGAR August 12, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Protagonist Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-266595) To Whom it May Concern: Pursu |
|
| August 5, 2022 |
Form of indenture of subordinated debt securities and related form of subordinated debt security. Exhibit 4.3 PROTAGONIST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities INDENTURE INDENTURE, dated as of [?], 202 , among PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [TRUSTEE] as trustee (the ?Trustee?): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and deliv |
|
| August 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Protagonist Therapeutics, Inc. |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission August 5, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission August 5, 2022 Registration No. |
|
| August 5, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 5, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Protagonist Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s c |
|
| August 5, 2022 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 PROTAGONIST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities INDENTURE INDENTURE, dated as of [●], 202 , among PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE] as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of |
|
| August 4, 2022 |
Exhibit 99.1 Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the 2022 ASCO Annual Meeting and the EHA2022 Congress Strong cash position, with cash runway through end of 2024 NEWARK, Calif., August 4, 20 |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| May 5, 2022 |
Exhibit 10.1 Protagonist Therapeutics Inc 7707 Gateway Blvd., Ste 140 Newark, CA 94560 United States of America Tel + 1 510 474 0170 Fax + 1 649 649 7377 www.protagonist-inc.com March 25, 2022 Asif Ali [email address] [telephone number] Dear Asif, On behalf of Protagonist, a biopharmaceutical company dedicated to discovering and developing peptides as novel pharmaceutical drugs, I am happy to exte |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAG |
|
| May 4, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2022 |
Exhibit 99.1 Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company?s primary point of focus Presented topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis with consistent treatment effects at the lower 150 mg BID dose across key end |
|
| April 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| April 26, 2022 |
1 PN - 943 Phase 2 Study Data Readout Dinesh V. Patel, PhD | President & CEO April 25, 2022 Exhibit 99.2 1 PN - 943 Phase 2 Study Data Readout Dinesh V. Patel, PhD | President & CEO April 25, 2022 Today?s Agenda 2 Introduction: Dinesh V. Patel, PhD, President & CEO Data readout from the Phase 2 IDEAL Study of PN - 943 in Ulcerative Colitis (UC): Scott Plevy, MD, Executive Vice President & Therapeutic Head, Gastroenterology Reflections on the data and the unmet need in UC : Bruce Sands, M |
|
| April 26, 2022 |
Exhibit 99.1 Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, g |
|
| April 13, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 13, 2022 |
1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO April 2022 Exhibit 99.1 1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO April 2022 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this pre sentation, i |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 13, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022. As filed with the Securities and Exchange Commission on February 28, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or organi |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| February 28, 2022 |
Exhibit 4.7 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (?we,? ?us,? ?our,? or the ?Company?). The following summaries and descriptions are not complete and are subject to and qualified by reference to t |
|
| February 28, 2022 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia ? |
|
| February 28, 2022 |
Exhibit 99.3 PROTAGONIST THERAPEUTICS, INC. AMENDED AND RESTATED 2018 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 29, 2018 EFFECTIVE DATE: MAY 29, 2018 AS AMENDED ON: FEBRUARY 15, 2022 1. GENERAL. (a) Purpose. This Plan, through the granting of Awards, is intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning o |
|
| February 28, 2022 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Protagonist Therapeutics, Inc. |
|
| February 28, 2022 |
Exhibit 99.1 Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in Q1 2022 Topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis expected in Q2 2022 Dosing has begun in a 240-patient Phase 2b clinical trial of PN-235 in moderate-to-sever |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2022 |
SC 13G/A 1 p22-0527sc13ga.htm PROTAGONIST THERAPEUTICS, INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2021 (Date of event which requires filing of t |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Protagonist Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PROTAGONIST THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 74366E102 (CUSIP Number) D |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2021 |
Exhibit 99.1 Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Resumption of the Phase 2 study of rusfertide in polycythemia vera now underway, following swift removal of the FDA clinical hold Positive proof -of- concept data for rusfertide in hereditary hemochromatosis to be presented at The Liver Meeting? hosted by the American Association for th |
|
| November 3, 2021 |
Exhibit 10.3 ? SECOND AMENDMENT TO LEASE ? THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 2nd day of July, 2021, by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership (?Landlord?), and PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (?Tenant?). ? RECITALS ? A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of Marc |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2021 |
Exhibit 10.1 ? EXECUTION COPY ? [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. ? AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN JANSSEN BIOTECH, INC. AND PROTAGONIST THERAPEUTICS, INC. |
|
| November 3, 2021 |
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. |
|
| September 21, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Protagonist Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $ |
|
| September 21, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| September 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17 , 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) |
|
| September 17, 2021 |
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program Exhibit 99.1 Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program NEWARK, Calif., September 17, 2021?Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (?Protagonist? or ?the Company?) today announced the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist?s clinical studies for rusfertide, an investigational produ |
|
| August 10, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2021 |
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress Exhibit 99.1 Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress NEWARK, Calif., August 4, 2021?Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (?Protagonist? or ?the Company?) today reported its financial results for the second quarter ended June 30, 2021, and an overview of recent company progress. ?The second quarter of 2021 was one of enormous progr |
|
| July 28, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| June 17, 2021 |
Title Of Each Class of Securities To Be Registered TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-251254? CALCULATION OF REGISTRATION FEE ? Title Of Each Class of Securities To Be Registered ? ? ? Amount To Be Registered ? ? ? Proposed Maximum Offering Price Per Unit ? ? ? Proposed Maximum Aggregate Offering Price ? ? ? Amount Of Registration Fee ? ? Common Stock, par value $0.00001 per share ? ? ? 3,503,311(1) ? ? ? $37.7 |
|
| June 17, 2021 |
Underwriting Agreement, dated June 15, 2021 Exhibit 1.1 3,046,358 Shares Protagonist Therapeutics, Inc. UNDERWRITING AGREEMENT June 15, 2021 J.P. MORGAN SECURITIES LLC JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minne |
|
| June 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2021 |
Subject to Completion Preliminary Prospectus Supplement dated June 14, 2021 424B5 1 tm2119593-1424b5.htm 424B5 TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these secur |
|
| June 14, 2021 |
Exhibit 99.1 PN - 943 PTG - 200 PN - 232 PN - 235 rusfertide (PTG - 300) PTG - 100 Dinesh V. Patel, PhD President & CEO June 2021 COMPANY OVERVIEW 1 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Reform Act of 1995. All statements other tha |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| May 4, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2021 |
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update NEWARK, California, May 4, 2021 ? Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or ?the Company?) today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update. ?Our progress this quarter affirms the strength of our pipeline and executio |
|
| May 4, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| April 14, 2021 |
Schedule 14A, filed with the SEC on April 14, 2021; DEF 14A 1 tm212463-1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 10, 2021 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia ? |
|
| March 10, 2021 |
Exhibit 4.7 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (?we,? ?us,? ?our,? or the ?Company?). The following summaries and descriptions are not complete and are subject to and qualified by reference to t |
|
| March 10, 2021 |
Exhibit 99.1 Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update - Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera - - Company expects to share findings from ongoing hereditary hemochromatosis study for rusfertide (PTG-300 |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 10, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2021 |
March 10, 2021 (File No. 333-254090) As filed with the Securities and Exchange Commission on March 10, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or organizat |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PROTAGONIST THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PROTAGONIST THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 74366E102 (CUSIP Number) D |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
Protagonist Therapeutics, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| February 2, 2021 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, $.00001 par value (Title of Class of Securities) 74366E102 (CUSIP Number) December 31, 2020 |
|
| December 14, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-251254 CALCULATION OF REGISTRATION FEE Title Of Each Class of Securities To Be Registered Amount To Be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount Of Registration Fee Common Stock, par value $0.00001 per share 5,476,189(1) $ 21.00 $ 114,999,969 $ 12,547(2) (1) Includes 7 |
|
| December 11, 2020 |
Underwriting Agreement, dated December 10, 2020. Exhibit 1.1 4,761,904 Shares Protagonist Therapeutics, Inc. UNDERWRITING AGREEMENT December 10, 2020 J.P. MORGAN SECURITIES LLC SVB LEERINK LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC 255 California St, 12th Floor San Francisco, California 94111 c/o Piper Sandler& Co. 800 Nicol |
|
| December 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| December 10, 2020 |
Exhibit 4.5 Protagonist Therapeutics, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Protagonist Therapeutics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Protagonist Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga |
|
| December 10, 2020 |
TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. |
|
| December 10, 2020 |
Form of Preferred Stock Warrant Exhibit 4.6 Protagonist Therapeutics, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Protagonist Therapeutics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Protagonist Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking associat |
|
| December 10, 2020 |
Form of Debt Securities Warrant Exhibit 4.7 Protagonist Therapeutics, inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Protagonist Therapeutics, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Protagonist therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking associat |
|
| December 10, 2020 |
Exhibit 4.3 PROTAGONIST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificat |
|
| December 10, 2020 |
As filed with the U.S. Securities and Exchange Commission on December 10, 2020 S-3ASR 1 tm2038033-1s3asr.htm S-3ASR TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on December 10, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Protagonist Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State |
|
| November 4, 2020 |
Exhibit 99.1 Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update - Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 - - PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera - - Company is advancing ad |
|
| November 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PR |
|
| November 4, 2020 |
Exhibit 99.2 Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting NEWARK, Calif., November 4, 2020 - Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Co |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of |
|
| September 11, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) ( |
|
| September 11, 2020 |
PTG - 300 Opportunity Update Dinesh V. Patel, PhD President & CEO 1 September 11, 2020 Exhibit 99.1 PTG - 300 Opportunity Update Dinesh V. Patel, PhD President & CEO 1 September 11, 2020 2 Forward Looking Statements This presentation contains forward - looking statements of Protagonist Therapeutics, Inc . (Protagonist) that involve substantial risks and uncertainties . All statements other than statements of historical facts contained in this presentation, including statements regar |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Com |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGO |
|
| August 6, 2020 |
Exhibit 10.1 EMPLOYEE SEVERANCE AGREEMENT This Employee Severance Agreement (this “Agreement”) is entered into as of the 4th day of August, 2020, by and between Protagonist Therapeutics, Inc., a Delaware corporation (the “Company”), and Donald Kalkofen (the “Employee”). Statement of Purpose Whereas, Employee is currently employed by the Company as an at-will employee; Whereas, notwithstanding the |
|
| August 6, 2020 |
Exhibit 99.1 Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update - Company to host webinar highlighting the PTG-300 program market opportunity in polycythemia vera - - PTG-300 received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of polycythemia vera - - Financial resources expected to support operations through mid-2 |
|
| June 8, 2020 |
PTGX / Protagonist Therapeutics, Inc. / Lilly Ventures Fund I LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* PROTAGONIST THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 74366E 102 (CUSIP Number) S. Edward Torres c/o LV Management Group, LLC 333 N. Alabama Street, Suite 350 Indianapolis, Indiana 46204 |
|
| May 29, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| May 22, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (CUSIP Number) May 13, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| May 13, 2020 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commis |
|
| May 12, 2020 |
Underwriting Agreement, dated as of May 11, 2020. Exhibit 1.1 Execution Version 7,000,000 Shares Protagonist Therapeutics, Inc. UNDERWRITING AGREEMENT May 11, 2020 JEFFERIES LLC BMO Capital Markets Corp. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o BMO Capital Markets Corp. 3 Times Square, 25th Floor New York, New York 10036 Ladies and Gentlemen: Introductory. Protagonist Therape |
|
| May 11, 2020 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 7, 2020 |
Exhibit 99.1 Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update - Company selects the polycythemia vera indication for pivotal development of PTG-300 based on robust clinical responses - - Revised and focused development plans now provide sufficient capital to fund operations through mid-2022 - - Protagonist to host a conference call today to provide a c |
|
| May 7, 2020 |
Exhibit 99.2 Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera - PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis - - Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Dis |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑37852 PROTAG |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Commiss |
|
| April 16, 2020 |
PTGX / Protagonist Therapeutics, Inc. DEFA14A - - DEFA14A DEFA14A 1 a20-21043defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 16, 2020 |
definitive proxy statement on Schedule 14A, filed with the SEC on April 16, 2020 DEF 14A 1 a2241314zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P |
|
| March 18, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 18, 2020 |
Letter of PricewaterhouseCoopers LLP dated March 18, 2020. Exhibit 16.1 March 18, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Protagonist Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Protagonist Therapeutics, Inc. dated March 13, 2020. We agree with the statements |
|
| March 10, 2020 |
March 10, 2020 (File No. 333-237066) As filed with the Securities and Exchange Commission on March 10, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROTAGONIST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 94-0505495 (State or other jurisdiction of incorporation or organizat |
|
| March 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑37852 PROTAGONIST |
|
| March 10, 2020 |
Exhibit 10.25 CREDIT AND SECURITY AGREEMENT dated as of October 30, 2019 by and among protagonist therapeutics, Inc., as a Borrower and any additional borrower that hereafter becomes party hereto, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO CREDIT AND SECURITY AGREEMENT This CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated |
|
| March 10, 2020 |
Exhibit 21.1 SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC. Subsidiary Jurisdiction of Formation/Organization Protagonist Pty Limited Australia |
|
| March 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (Comm |
|
| March 10, 2020 |
Exhibit 99.1 Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results - Therapeutic candidate PTG-300 under evaluation in Phase 2 proof of concept studies in multiple blood disorder indications - - Two differentiated, orally administered candidates PTG-200 and PN-943 in clinical-stage development for the treatment of inflammatory bowel disease - - Sufficient financial r |
|
| March 10, 2020 |
EX-4.7 2 ptgx-20191231ex4743c3fa2.htm EX-4.7 Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (“we,” “us,” “our,” or the “Company”). The following summaries and descriptions are not complete and are s |
|
| February 24, 2020 |
Exhibit 10.1 Protagonist Therapeutics, Inc. Amended and Restated 2018 Inducement Plan Adopted by the Board of Directors: May 29, 2018 Effective Date: May 29, 2018 As Amended on: February 18, 2020 1. General. (a) Purpose. This Plan, through the granting of Awards, is intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning o |
|
| February 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37852 98-0505495 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E 102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2020 |
PTGX / Protagonist Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E 102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
